Author: Batra, Neelu; De Souza, Cristabelle; Batra, Jyoti; Raetz, Alan G.; Yu, Ai-Ming
Title: The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19) Cord-id: msbq3ynt Document date: 2020_9_3
ID: msbq3ynt
Snippet: The coronavirus disease of 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global pandemic with increasing incidence and mortality rates. Recent evidence based on the cytokine profiles of severe COVID-19 cases suggests an overstimulation of macrophages and monocytes associated with reduced T-cell abundance (lymphopenia) in patients infected with SARS-CoV-2. The SARS-CoV-2 open reading frame 3 a (ORF3a) protein was found to bind to the human HMOX1 pr
Document: The coronavirus disease of 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global pandemic with increasing incidence and mortality rates. Recent evidence based on the cytokine profiles of severe COVID-19 cases suggests an overstimulation of macrophages and monocytes associated with reduced T-cell abundance (lymphopenia) in patients infected with SARS-CoV-2. The SARS-CoV-2 open reading frame 3 a (ORF3a) protein was found to bind to the human HMOX1 protein at a high confidence through high-throughput screening experiments. The HMOX1 pathway can inhibit platelet aggregation, and can have anti-thrombotic and anti-inflammatory properties, amongst others, all of which are critical medical conditions observed in COVID-19 patients. Here, we review the potential of modulating the HMOX1-ORF3a nexus to regulate the innate immune response for therapeutic benefits in COVID-19 patients. We also review other potential treatment strategies and suggest novel synthetic and natural compounds that may have the potential for future development in clinic.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and long period: 1, 2
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lung thrombosis: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung thrombosis sepsis: 1
- acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and m1 macrophage: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and macrophage differentiation: 1, 2, 3
- acute ards respiratory distress syndrome and macrophage dysfunction: 1, 2
- acute ards respiratory distress syndrome cause and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute ards respiratory distress syndrome cause and lung tissue: 1, 2, 3, 4
- acute ards respiratory distress syndrome cause and macrophage dysfunction: 1
- long period and lung injury: 1
- long period and lung tissue: 1, 2
- lung injury and m1 macrophage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lung injury and macrophage differentiation: 1
- lung injury and macrophage dysfunction: 1, 2
- lung tissue and m1 macrophage: 1, 2, 3, 4
- lung tissue and macrophage differentiation: 1, 2
Co phrase search for related documents, hyperlinks ordered by date